Meliva Kardiolita Hospital
| Lituânia | Turquia | Áustria | |
| Terapia com células estaminais para ELA (esclerose lateral amiotrófica) | - | de $30,000 | de $60,000 |
| Terapia com Células Estaminais | - | de $4,675 | de $8,500 |
| Plasmaférese | - | de $1,200 | de $2,000 |
A Bookimed não adiciona taxas extras aos preços de tratamento de Esclerose lateral amiotrófica. As tarifas vêm das listas oficiais de preços das clínicas. O pagamento é feito diretamente na clínica na chegada ao país.
A Bookimed está comprometida com sua segurança. Trabalha apenas com instituições que mantêm altos padrões internacionais no tratamento de Esclerose lateral amiotrófica e têm as licenças necessárias para atender pacientes internacionais em todo o mundo.
A Bookimed oferece assistência gratuita de especialistas. Um coordenador médico pessoal apoia antes, durante e após o tratamento, solucionando problemas. Nunca está sozinho em sua jornada de tratamento de Esclerose lateral amiotrófica.
ALS is currently incurable in Lithuania and worldwide. It is a progressive neurodegenerative disease without a known reversal. Lithuanian clinics focus on managing symptoms and slowing progression. Treatments align with European Union standards to enhance patient quality of life.
Bookimed Expert Insight: Patients seeking specialized care in Lithuania should prioritize JCI-accredited facilities in Vilnius. While no clinic offers a cure, big centers like Meliva Kardiolita treat 298,000 patients yearly. This high volume often ensures faster access to multidisciplinary neurological diagnostics. This speed is vital for managing early-stage symptoms effectively.
Patient Consensus: Patients emphasize sticking to accredited neurologists rather than unproven clinics. They note that coordinating early respiratory and physical therapy is essential for daily comfort.
Amyotrophic lateral sclerosis patients in Lithuania can access riluzole, the primary medication authorized by the European Medicines Agency to slow disease progression. Most patients receive this via the national health system. Specialized clinics also provide edaravone infusions and mesenchymal stem cell therapies to manage inflammation and functional decline.
Bookimed Expert Insight: Lithuania is a strategic choice for neurological care because private centers like Medical Diagnostic and Treatment Center provide rapid diagnostic access. While the public system covers riluzole fully, international patients often use private facilities to bypass wait times for neurologists. Major Vilnius hospitals utilize JCI-accredited standards, ensuring medication protocols match top Western European centers at a lower secondary cost.
Patient Consensus: Patients emphasize starting riluzole immediately upon diagnosis and note that doctors in the Baltic region are often more open to prescribing B12 injections for breathing support.
Lithuanian ALS centers integrate neurology, genetics, and respiratory care into a single clinical path. Centers like Vilnius University Hospital Santaros Klinikos follow European standards. They provide diagnostic electromyography, genetic counseling, and physical rehabilitation. Teams focus on mobility preservation and non-invasive ventilation for breathing support.
Bookimed Expert Insight: Private clinics in Vilnius provide an additional layer of logistical support for patients. Meliva Kardiolita Hospital and the Medical Diagnostic and Treatment Center are JCI-accredited. This certification ensures they maintain international safety standards across their 30+ departments. While university hospitals lead in ALS research, these private centers offer faster access to high-quality diagnostics and physical rehabilitation. This availability helps avoid delays in managing progressive muscle weakness.
Patient Consensus: Patients note it is important to connect with local support groups early. This helps unlock bundled services like physical therapy and psychological support. They also suggest requesting written care plans after multidisciplinary meetings to ensure treatments stay coordinated.
Lithuania coordinates amyotrophic lateral sclerosis (ALS) care through Vilnius University Hospital Santaros Klinikos and Kaunas Clinics. These tertiary centers provide multidisciplinary diagnostics. They use electromyography and genetic testing to evaluate neuromuscular disorders. Patients often access international standards via the European Reference Networks for rare diseases.
Bookimed Expert Insight: Clinical data shows a high concentration of expertise in Vilnius. Meliva Kardiolita Hospital alone treats 298,000 patients annually. While university hospitals handle complex genetic research, private centers like the Medical Diagnostic and Treatment Center excel in diagnostic speed. This allows patients to bypass the long wait times common in the public sector. Use these centers for initial confirmation, then integrate with university hospitals for long-term genetic follow-ups.
Patient Consensus: Patients note that major university hospitals provide reliable basic care and medication. Many advise joining European networks for access to clinical trials not yet available locally.
Lithuania offers experimental stem-cell therapy for ALS using Mesenchymal Stem Cells (MSCs). The treatment focuses on neuroprotection and reducing inflammation in the central nervous system. Procedures are available at private clinics under the Law on Ethics of Biomedical Research and national transplantation regulations.
Bookimed Expert Insight: While Lithuania has reputable JCI-accredited hospitals like Meliva Kardiolita and the Medical Diagnostic and Treatment Center, they specialize primarily in diagnostics and rehabilitation. Our data shows that high-volume centers for experimental cell therapies are often separate from these surgical hubs. Always confirm if a clinic’s specific ALS protocol is registered in the EU Clinical Trials Register before traveling.
Patient Consensus: Patients emphasize the need for caution with private clinics and often check for published peer-reviewed data. Many note that while they feel hope, they worry about the lack of long-term follow-up statistics.